Human Reproductive Technologies Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 2.00 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Human Reproductive Technologies Market Analysis
The global human reproductive technologies market is anticipated to grow with a CAGR of nearly 2% during the forecast period. Rising prevalence of infertility and delayed family planning is expected to trigger the market growth. As per the US Department of Health & Human Services, one out of 100 couples are facing problem in conceiving, leading to the adoption of reproductive technologies to treat infertility rate which is further triggering the market growth. Moreover, change in lifestyle such as delay in bearing the first child, use of contraceptive pills, increased alcohol consumption and smoking is leading to increasing infertility rates and is providing a significant boost to the market. Growing patient awareness regarding the available technologies for treating problems related to reproduction is projected to increase the adoption of human reproductive technologies. However, Limited Insurance Coverage may restrain the growth of the market.
Human Reproductive Technologies Market Trends
This section covers the major market trends shaping the Human Reproductive Technologies Market according to our research experts:
Contraceptive Segment is Expected to Hold a Major Market Share in the Human Reproductive Technologies Market
A contraceptive segment is expected to hold the largest segment owing to oral drugs are the easiest way of contraception in the industry, easy availability of a wide range of products, high awareness about contraceptive drugs and devices and simple mode of administration are the key factors triggering the segment growth. Moreover, increasing incidences of the Sexually Transmitted Disease (STD), an increasing rate of unplanned pregnancies and a rise in government initiatives are also some of the factors propelling the contraceptive drugs and devices segment.
North America Represents the Largest Market and Asia-Pacific is Expected to Register Fastest Growth.
North America is at the forefront of growth in the market studied and is also an important revenue contributor in the global arena. Rise in infertility rates due to high obesity rates, the rising age of conceptions and changes in lifestyle are stimulating the growth of the region. As per the US Department of Health & Human Services, an estimated 10% of women (6.1 million) in the United States are unable to conceive. Moreover, easy access to quality healthcare and favorable reimbursement policies are projected to promote revenue growth in North America.
The Asia Pacific region is likely to post the fastest market throughout the forecast period. The highest population, increasing awareness about reproductive technologies, rapid adoption of western lifestyle has led to the adoptions of these reproductive technologies. In addition, increasing healthcare spending is expected to propel the market in the APAC region.
Human Reproductive Technologies Industry Overview
The Human Reproductive Technologies Market is fragmented in terms of competition and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are CooperSurgical, Inc., Teva Pharmaceutical Industries, AbbVie Inc., Ferring B.V., Merck KGaA, Genea Limited, and Ivftech.
Human Reproductive Technologies Market Leaders
-
CooperSurgical
-
Teva Pharmaceutical Industries
-
AbbVie Inc.
-
Ferring B.V
-
Merck KGaA
*Disclaimer: Major Players sorted in no particular order
Human Reproductive Technologies Market Report - Table of Contents
-
1. INTRODUCTION
-
1.1 Study Assumptions
-
1.2 Scope of the Study
-
-
2. RESEARCH METHODOLOGY
-
3. EXECUTIVE SUMMARY
-
4. MARKET DYNAMICS
-
4.1 Market Overview
-
4.2 Market Drivers
-
4.2.1 Rising Prevalence of Infertility
-
4.2.2 Delayed Family Planning
-
-
4.3 Market Restraints
-
4.3.1 Limited Insurance Coverage
-
-
4.4 Porter's Five Force Analysis
-
4.4.1 Threat of New Entrants
-
4.4.2 Bargaining Power of Buyers/Consumers
-
4.4.3 Bargaining Power of Suppliers
-
4.4.4 Threat of Substitute Products
-
4.4.5 Intensity of Competitive Rivalry
-
-
-
5. MARKET SEGMENTATION
-
5.1 By Reproductive Technology
-
5.1.1 Infertility Treatment
-
5.1.1.1 Drugs
-
5.1.1.1.1 Follitropin Alfa
-
5.1.1.1.2 Follitropin Beta
-
5.1.1.1.3 Menotropins
-
5.1.1.1.4 Others
-
-
5.1.1.2 Devices
-
5.1.1.2.1 Sperm Separation Devices
-
5.1.1.2.2 Sperm Analyzer Systems
-
5.1.1.2.3 Ovum Aspiration Pumps
-
5.1.1.2.4 Micromanipulator Systems
-
5.1.1.2.5 Others
-
-
-
5.1.2 Contraceptive
-
5.1.2.1 Drugs
-
5.1.2.1.1 Oral Contraceptives
-
5.1.2.1.2 Topical Contraceptives
-
5.1.2.1.3 Contraceptive Injectable
-
-
5.1.2.2 Devices
-
5.1.2.2.1 Condoms
-
5.1.2.2.2 IUD
-
5.1.2.2.3 Cervical Caps
-
5.1.2.2.4 Diaphragms
-
5.1.2.2.5 Others
-
-
-
-
5.2 By Gender
-
5.2.1 Male
-
5.2.2 Female
-
-
5.3 Geography
-
5.3.1 North America
-
5.3.1.1 United States
-
5.3.1.2 Canada
-
5.3.1.3 Mexico
-
-
5.3.2 Europe
-
5.3.2.1 Germany
-
5.3.2.2 United Kingdom
-
5.3.2.3 France
-
5.3.2.4 Italy
-
5.3.2.5 Spain
-
5.3.2.6 Rest of Europe
-
-
5.3.3 Asia-Pacific
-
5.3.3.1 China
-
5.3.3.2 Japan
-
5.3.3.3 India
-
5.3.3.4 Australia
-
5.3.3.5 South Korea
-
5.3.3.6 Rest of Asia-Pacific
-
-
5.3.4 Middle-East and Africa
-
5.3.4.1 GCC
-
5.3.4.2 South Africa
-
5.3.4.3 Rest of Middle-East and Africa
-
-
5.3.5 South America
-
5.3.5.1 Brazil
-
5.3.5.2 Argentina
-
5.3.5.3 Rest of South America
-
-
-
-
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
-
6.1.1 CooperSurgical, Inc.
-
6.1.2 Teva Pharmaceutical Industries
-
6.1.3 AbbVie Inc.
-
6.1.4 Ferring B.V.
-
6.1.5 Merck KGaA
-
6.1.6 Genea Limited
-
6.1.7 Ivftech
-
6.1.8 Bayer AG
-
- *List Not Exhaustive
-
-
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Human Reproductive Technologies Industry Segmentation
As per the scope of the report, Human reproductive technologies involves all current and anticipated uses of technology in reproduction, including infertility treatments, contraceptives drugs and devices. These technologies deals with treating the infertility problems and conceiving.
| By Reproductive Technology | |||||||||||||||
| |||||||||||||||
|
| By Gender | |
| Male | |
| Female |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Human Reproductive Technologies Market Research FAQs
What is the current Human Reproductive Technologies Market size?
The Human Reproductive Technologies Market is projected to register a CAGR of 2% during the forecast period (2024-2029)
Who are the key players in Human Reproductive Technologies Market?
CooperSurgical, Teva Pharmaceutical Industries, AbbVie Inc., Ferring B.V and Merck KGaA are the major companies operating in the Human Reproductive Technologies Market.
Which is the fastest growing region in Human Reproductive Technologies Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Human Reproductive Technologies Market?
In 2024, the North America accounts for the largest market share in Human Reproductive Technologies Market.
What years does this Human Reproductive Technologies Market cover?
The report covers the Human Reproductive Technologies Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Human Reproductive Technologies Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Human Reproductive Technologies Industry Report
Statistics for the 2024 Human Reproductive Technologies market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Human Reproductive Technologies analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
